Joy Schechtman, DO
Rheumatology · Peoria, AZNPI 1649244716
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $641,664 of the $860,187 with a category attached, or 74.6%. It is spread thinly across 58 manufacturers, the largest accounting for just 20.9%. Among rheumatology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,562 payments — averaging $335.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$180K
- UCB, Inc.$107K
- AbbVie$107K
- Lilly USA, LLC$94K
- Boehringer Ingelheim$75K
- Mallinckrodt Hospital Products Inc.$55K
- plus $243K from 52 others
Across 397 payments — averaging $3148.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$604K
- AbbVie$460K
- Hexal AG$57K
- Eli Lilly$52K
- Janssen Research & Development, LLC$18K
- UCB SA$13K
- plus $46K from 8 others
What the payments were for
- Consulting fees$108,04613%
- Speaking & faculty fees$641,66475%
- Grants$2400%
- Travel & lodging$59,8377%
- Food & beverage$49,6476%
- Education$6960%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$860,187 in reported general payments places this provider in the 95th percentile of 102 rheumatology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 73 | $880,134 |
| ProliaDenosumab | 290 | $506,322 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 52 | $126,996 |
| Xeljanz XrTofacitinib Citrate | 21 | $118,089 |
| Humira(Cf)Adalimumab | 12 | $89,480 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 12 | $87,481 |
| TymlosAbaloparatide | 32 | $85,304 |
| Hydroxychloroquine Sulfate | 681 | $27,526 |
| MethotrexateMethotrexate Sodium | 1,643 | $25,371 |
| Bosentan | 11 | $13,690 |
| Celecoxib | 288 | $11,453 |
| Fluconazole | 96 | $8,219 |
| Risedronate Sodium DrRisedronate Sodium | 19 | $7,423 |
| Gabapentin | 405 | $7,048 |
| Colchicine | 63 | $6,886 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $75,241 | $880,13473 claims |
| AmgenProlia, Evenity (2 Syringes) | $180,129 | $633,318342 claims |
| AbbVieHumira(Cf) | $106,508 | $89,48012 claims |
| Radius Health, Inc.Tymlos | $22,497 | $85,30432 claims |
| Actelion Pharmaceuticals US, Inc.Bosentan | $499 | $13,69011 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $18 | $6,88663 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 102 rheumatology providers in Arizona.
Other rheumatology in Peoria
- Orwah Al-KhaliliPeoria$20K
- Varun BhallaPeoria$7K
- Ravi BhallaPeoria$5K
- Terrence PrasadPeoria$2K
- Nehad SolomanPhoenix$1.3M
- John TesserPhoenix$999K
- Mona AminGlendale$446K
- Brittany PanicoGilbert$374K
- Amer Al-KhoudariChandler$369K
- Andrew SharobeemGlendale$231K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.